The estimated Net Worth of Rajiv Malik is at least $22.6 Million dollars as of 28 August 2024. Mr. Malik owns over 100,000 units of Mylan NV stock worth over $956,056 and over the last 10 years he sold MYL stock worth over $9,307,590. In addition, he makes $12,375,800 as President und Executive Director at Mylan NV.
Rajiv has made over 18 trades of the Mylan NV stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 100,000 units of MYL stock worth $1,195,000 on 28 August 2024.
The largest trade he's ever made was exercising 608,718 units of Mylan NV stock on 2 March 2024 worth over $9,648,180. On average, Rajiv trades about 100,074 units every 120 days since 2015. As of 28 August 2024 he still owns at least 60,319 units of Mylan NV stock.
You can see the complete history of Mr. Malik stock trades at the bottom of the page.
Rajiv Malik serves as President, Executive Director of the Company. Mr. Malik is responsible for the day-to-day operations of the Company, which includes Commercial, Scientific Affairs, Manufacturing, Supply Chain and Quality. In his role, he also oversees Business Development and Information Technology. Previously, Mr. Malik held various senior roles at Mylan, including executive vice president and chief operating officer from July 2009 to December 2012, and head of Global Technical Operations from January 2007 to July 2009. Mr. Malik has been integral in developing the strategies for the Company’s acquisitions, and, in the execution and integration of acquisitions, including the generics business of Merck KGaA; the injectables business of Bioniche; Agila Specialties, a global injectables company; the EPD Business; Famy Care’s women’s healthcare businesses; Meda, a leading international specialty pharmaceutical company that sells prescription and OTC products; and the non-sterile, topicals-focused business of Renaissance Acquisition Holdings, LLC.
As the President und Executive Director of Mylan NV, the total compensation of Rajiv Malik at Mylan NV is $12,375,800. There are 1 executives at Mylan NV getting paid more, with Heather Bresch having the highest compensation of $18,509,300.
Rajiv Malik is 59, he's been the President und Executive Director of Mylan NV since 2016. There are 8 older and 3 younger executives at Mylan NV. The oldest executive at Mylan NV is Robert Cindrich, 76, who is the Non-Executive Independent Director.
Rajiv's mailing address filed with the SEC is 1000 MYLAN BOULEVARD, , CANONSBURG, PA, 15317.
Over the last 10 years, insiders at Mylan NV have traded over $1,861,785,794 worth of Mylan NV stock and bought 202,008 units worth $5,767,632 . The most active insiders traders include Laboratories Abbott Product..., Daniel Martin Jr Gallagher und Robert J Coury. On average, Mylan NV executives and independent directors trade stock every 15 days with the average trade being worth of $5,605,891. The most recent stock trade was executed by Robert J Cindrich on 16 November 2020, trading 9,440 units of MYL stock currently worth $149,624.
Mylan NV is a pharmaceutical healthcare company. The firm engages in the development, license, manufacture, market and distribution of generic, branded generic and specialty pharmaceutical products. It operates through the following geographical segments: North America, Europe and Rest of World. The North America segment develops, manufactures, sells, and distributes pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized and cream, or ointment form. The Europe segment operates through subsidiaries in Italy, Germany, the United Kingdom, and Spain. The Rest of World segment comprises of operations in Japan, Australia, China, Brazil, Russia, India, South Africa, Middle East and South East Asia. The company was founded in 1961 and is headquartered in Hatfield, the United Kingdom.
Mylan NV executives and other stock owners filed with the SEC include: